Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IOVA | 8-K | neutral | 4/10 | Iovance Biotherapeutics filed an 8-K to update its corporate presentation, highlighting strong Q2 2026 revenue of ~$99M | Oct 5, 2026 |
| NRXP | 8-K | bullish | 6/10 | NRx Pharmaceuticals' subsidiary, NRx Defense Systems, was awarded an $11.2 million prime contract from DARPA to conduct | Oct 5, 2026 |
| PASG | S-4/A | neutral | 5/10 | Passage Bio filed Amendment No. 3 to its S-4 registration statement for the proposed reverse merger with Remix Therapeut | Oct 5, 2026 |
| UTHR | CLUSTER | bearish | 5/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$818K in open-market sales on October 1-2, 2026. The CEO's sal | Oct 5, 2026 |
| ADIA | 8-K | neutral | 5/10 | Adia Med, Inc. filed a declaratory judgment action in Florida state court seeking to quiet title to 29,059,792 shares (3 | Oct 5, 2026 |
| OSTX | 3 | neutral | 2/10 | Francis Knuettel II, the newly appointed Chief Financial Officer of OS Therapies Inc, filed a Form 3 initial statement o | Oct 5, 2026 |
| OPTH | SC 13G/A | neutral | 3/10 | YA II PN, Ltd. filed an amended Schedule 13G disclosing a 3.0% passive stake (173,000 shares) in Optimi Health Corp. as | Oct 5, 2026 |
| AMLX | 144 | neutral | 3/10 | Director George M. Milne Jr. filed a Form 144 notice of intent to sell 100,000 shares of Amylyx Pharmaceuticals (AMLX), | Oct 5, 2026 |
| PPBT | 6-K | neutral | 2/10 | Purple Biotech announced the appointment of former CEO and current board member Isaac Israel as Interim CEO, effective O | Oct 5, 2026 |
| OSTX | 8-K | neutral | 5/10 | OS Therapies appointed Frank Knuettel II as CFO and Kerry Clem as CCO, replacing outgoing CFO Christopher Acevedo. The p | Oct 5, 2026 |
| USNA | 8-K | neutral | 3/10 | USANA entered into a First Amendment to its existing credit agreement with Bank of America, N.A. and other lenders. The | Oct 5, 2026 |
| FHTX | 3 | neutral | 2/10 | BVF entities (Biotechnology Value Fund, BVF Partners, and affiliates) filed a Form 3 initial statement of beneficial own | Oct 5, 2026 |
| FHTX | SC 13G/A | neutral | 4/10 | Biotechnology Value Fund L.P. (BVF) and affiliated entities filed an amended Schedule 13G on October 5, 2026, reporting | Oct 5, 2026 |
| SYRE | 424B5 | bearish | 5/10 | Spyre Therapeutics filed a preliminary 424B5 prospectus supplement for an underwritten common stock offering of an undis | Oct 5, 2026 |
| KRRO | 8-K | neutral | 4/10 | Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated R | Oct 5, 2026 |
| SLXN | DEF 14A | bearish | 7/10 | Silexion Therapeutics is holding an extraordinary general meeting on October 19, 2026 to seek shareholder approval for t | Oct 5, 2026 |
| ABBV | 8-K | neutral | 4/10 | AbbVie filed an 8-K updating its full-year 2026 adjusted diluted EPS guidance to $13.76-$13.96, incorporating a $216 mil | Oct 5, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Two C-suite insiders at Castle Biosciences sold a total of ~$136K in open-market sales over a 3-day period. The Chief Co | Oct 5, 2026 |
| SBFM | SC 13G/A | bearish | 5/10 | Alta Partners LLC filed an amended Schedule 13G disclosing a 4.9% passive stake in Sunshine Biopharma Inc., consisting o | Oct 5, 2026 |
| TBPH | 15-12G | bearish | 7/10 | Theravance Biopharma filed a Form 15 to terminate its SEC registration and suspend reporting obligations, effective Octo | Oct 5, 2026 |
| TWST | CLUSTER | bearish | 5/10 | Two insiders at Twist Bioscience sold a combined $2.08M in open-market sales on the same day, including the Chief Accoun | Oct 5, 2026 |
| ALMR | PRESS-RELEASE | neutral | 2/10 | Alamar Biosciences announced the appointment of Bob Ragusa (former CEO of GRAIL and COO of Illumina) to its board of dir | Oct 5, 2026 |
| KRRO | PRESS-RELEASE | neutral | 4/10 | Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated R | Oct 5, 2026 |
| EQ | PRESS-RELEASE | neutral | 4/10 | Equillium received Australian regulatory clearance (HREC approval and TGA clearance) to begin a Phase 1 trial of EQ504, | Oct 5, 2026 |
| ORIC | PRESS-RELEASE | bullish | 6/10 | ORIC Pharmaceuticals announced a partnership with Cancer Research UK to fully fund and execute CTA-enabling studies and | Oct 5, 2026 |
| SYRE | PRESS-RELEASE | bearish | 5/10 | Spyre Therapeutics announced an underwritten public offering of common stock, with an underwriter option for an addition | Oct 5, 2026 |
| BBIO | PRESS-RELEASE | neutral | 2/10 | BridgeBio Pharma announced a nationwide education campaign to raise awareness of ATTR cardiac amyloidosis (ATTR-CM), inc | Oct 5, 2026 |
| KMDA | 6-K | neutral | 2/10 | Kamada Ltd. filed a 6-K responding to an SEC comment letter regarding its 2025 Form 20-F. The company clarified it did n | Oct 5, 2026 |
| GMAB | 6-K | bullish | 7/10 | Genmab and AbbVie announced positive topline Phase 3 results for epcoritamab + R-CHOP in newly diagnosed DLBCL, showing | Oct 5, 2026 |
| ARQT | SC 13G/A | neutral | 3/10 | BlackRock filed an amended Schedule 13G disclosing a 14.1% passive stake in Arcutis Biotherapeutics as of September 30, | Oct 5, 2026 |